APUS vs EMR · $2.4M cap vs P/E 34, rev $4.86B
Apimeds Pharmaceuticals US, Inc. (APUS) versus Emerson Electric Company (EMR) — a side-by-side from cached financials, not a winner call.
Apimeds Pharmaceuticals US, Inc. (APUS) is a drug manufacturers - specialty & generic company listed on US.
Emerson Electric Company (EMR) is a specialty industrial machinery company listed on NYSE.
APUS does not have a complete income-statement cache yet.
Latest reported EMR revenue for 2025-09-30 was $4.86B. Net income was $2.25B. Revenue was up 6.6% from 2025-06-30 to 2025-09-30. EMR currently screens at market cap $83.45B and trailing P/E 34.5.
APUS currently screens at market cap $2.4M. EMR currently screens at market cap $83.45B and trailing P/E 34.5.
Not investment advice. Open the APUS and EMR stock pages for the full models.
Not investment advice.